Two weeks ago I posted that if Hydroxychloroquine had been readily used the Covid crisis would be over by now. I said the real reason for the vilification of HCQ is that being an old drug on the market for over 50 years, no one is going to get rich off it. On the other hand some new drugs not yet on the market have the potential to quite handsomely reward those who make these drugs as well as those who own stock in Big Pharma. It’s been rumored that Dr. Fauci owns such stocks which will do well when these new drugs hit the market. They don’t want to have to compete with HCQ which is now priced quite low because its patent has run out.
That’s a bold statement that says Pharma and antii-HCQ doctors are placing their own financial interests ahead of effective treatment of Covid patients, at least those patients in the early stages of Covid.
Now a highly esteemed epidemiologist has written a piece in the Washington Examiner that says much the same.
Harvey Risch, M.D., Ph.D., is a professor of epidemiology at Yale School of Public Health. Here is what he wrote:
It is a serious and unconscionable mistake that the FDA has used inpatient data to block emergency use petitions for outpatient use. Further, already back in March, the FDA approved the emergency use of hydroxychloroquine for hospitalized patients, for whom it is demonstrably less effective than for outpatients. If hydroxychloroquine satisfied the FDA criteria for emergency inpatient use in March, it should more than satisfy those criteria now for outpatient use, where the evidence is much stronger.
I can only speculate about the cause of the FDA’s recalcitrance. Hydroxychloroquine is an inexpensive, generic medication. Unlike certain profit-generating, patented medications, which have been promiscuously touted on the slimmest of evidence, hydroxychloroquine has no natural financial constituency. No one will get rich from it.
Further, it seems quite possible that the FDA, a third of whose funding comes from drug companies, is under intense pressure from those companies to be extremely conservative in its handling of hydroxychloroquine. If hydroxychloroquine is used widely and comes to be recognized as highly effective, the markets for expensive and patented COVID-19 medications, including intravenous drugs that can only be used in the hospital, will shrink substantially.
Whatever the reason for the FDA’s stonewalling on hydroxychloroquine, this much is certain: Americans are dying unnecessarily, the economy is in disarray, and the threads that bind our society together have frayed. I am speaking out, but where is everyone else? Where are our elected officials, including those who are themselves physicians? Some, including Rep. Andy Biggs of Arizona, have been discussing evidence of the drug’s effectiveness, but where are the rest?
This issue should not be a partisan one. If our elected officials are not willing to pry open the FDA, we must elect new officials. Why are we silent? The time to speak is now.
I don’t know Dr. Risch and he does not know me. I doubt he has or ever will read what I wrote. I thank Dr. Risch for his seminal article that brings wisdom and common sense to bear on all the demonization of HCQ.
I urge my readers to read and study Dr. Risch’s entire article published 2 days ago. In the first part of his article he makes the claim that Dr. Fauci is spreading disinformation. He’s correct. It’s about time someone has the courage to question this grand stander.